

Wright Medical Group, Inc.
Reconciliation of Net Sales to Net Sales Excluding the Impact of Foreign Currency
(dollars in thousands--unaudited)

	Three Months Ended June 30, 2008		Six Months Ended June 30, 2008	
	International Net Sales	Total Net Sales	International Net Sales	Total Net Sales
Net sales, as reported	\$ 49,336	\$ 118,477	\$ 97,983	\$ 234,342
Currency impact as compared to prior period	(4,174)	(4,174)	(8,252)	(8,252)
Net sales, excluding the impact of foreign currency	\$ 45,162	\$ 114,303	\$ 89,731	\$ 226,090

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(in thousands, except per share data--unaudited)

	Three Months Ended June 30, 2008		Six Months Ended June 30, 2008	
	June 30, 2008	June 30, 2007	June 30, 2008	June 30, 2007
Operating Income				
Operating (loss) income, as reported	\$ (448)	\$ (2,431)	\$ 5,535	\$ 2,008
<i>Reconciling items impacting Gross Profit:</i>				
Inventory step-up amortization	-	200	73	200
Non-cash, stock-based compensation	308	542	652	1,033
Total	308	742	725	1,233
<i>Reconciling items impacting Selling, General and Administrative expenses:</i>				
Non-cash, stock-based compensation	2,846	2,934	5,817	5,894
Department of Justice inquiry	1,462	-	3,186	-
Appellate court decision	2,346	-	2,346	-
Total	6,654	2,934	11,349	5,894
<i>Reconciling items impacting Research and Development expenses:</i>				
Non-cash, stock-based compensation	417	336	666	1,617
<i>Other Reconciling Items:</i>				
Restructuring charges	3,095	7,539	4,910	7,539
Acquired in-process research and development	2,490	-	2,490	-
Total	5,585	7,539	7,400	7,539
Operating income, as adjusted	\$ 12,516	\$ 9,120	\$ 25,675	\$ 18,291
Operating income, as adjusted, as a percentage of net sales	10.6%	9.3%	11.0%	9.5%

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(continued)

	Three Months Ended June 30, 2008		Six Months Ended June 30, 2008	
	June 30, 2008	June 30, 2007	June 30, 2008	June 30, 2007
Net Income				
Net (loss) income, as reported	\$ (2,357)	\$ (2,090)	\$ 1,701	\$ 1,099
<i>Pre-tax impact of reconciling items:</i>				
Non-cash, stock-based compensation	3,571	3,812	7,135	8,544
Restructuring charges	3,095	7,539	4,910	7,539
Inventory step-up amortization	-	200	73	200
Department of Justice inquiry	1,462	-	3,186	-
Appellate court decision (including interest)	2,638	-	2,638	-
Acquired in-process research and development	2,490	-	2,490	-
Total	13,256	11,551	20,432	16,283
<i>Tax effect of reconciling items:</i>				
Non-cash, stock-based compensation	(1,061)	(817)	(1,980)	(2,083)
Restructuring charges	(1,067)	(2,526)	(1,730)	(2,526)
Inventory step-up amortization	-	-	(29)	-
Department of Justice inquiry	(576)	-	(1,256)	-
Appellate court decision	(1,039)	(78)	(1,039)	(78)
Acquired in-process research and development	-	-	-	-
Total	(3,743)	(3,421)	(6,034)	(4,687)
Net income, as adjusted	\$ 7,156	\$ 6,040	\$ 16,099	\$ 12,695
			Three Months Ended June 30, 2008	Three Months Ended June 30, 2007
	As Reported	As Adjusted	As Reported	As Adjusted
Basic net (loss) income	\$ (2,357)	\$ 7,156	\$ (2,090)	\$ 6,040
Interest expense on convertible notes	N/A	937	N/A	N/A
Diluted net (loss) income	\$ (2,357)	\$ 8,093	\$ (2,090)	\$ 6,040
Basic shares	36,832	36,832	35,654	35,654
Dilutive effect of stock options and restricted shares	-	663	-	710
Dilutive effect of convertible notes	-	6,126	N/A	N/A
Diluted shares	36,832	43,621	35,654	36,364
Net (loss) income per share, diluted	\$ (0.06)	\$ 0.19	\$ (0.06)	\$ 0.17
			Six Months Ended June 30, 2008	Six Months Ended June 30, 2007
	As Reported	As Adjusted	As Reported	As Adjusted
Basic net income	\$ 1,701	\$ 16,099	\$ 1,099	\$ 12,695
Interest expense on convertible notes	N/A	1,874	N/A	N/A
Diluted net income	\$ 1,701	\$ 17,973	\$ 1,099	\$ 12,695
Basic shares	36,718	36,718	35,468	35,468
Dilutive effect of stock options and restricted shares	595	595	669	669
Dilutive effect of convertible notes	-	6,126	N/A	N/A
Diluted shares	37,313	43,439	36,137	36,137
Net income per share, diluted	\$ 0.05	\$ 0.41	\$ 0.03	\$ 0.35

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(continued)

	<u>Three Months Ended</u>		<u>Six Months Ended</u>	
	<u>June 30,</u> <u>2008</u>	<u>June 30,</u> <u>2007</u>	<u>June 30,</u> <u>2008</u>	<u>June 30,</u> <u>2007</u>
Net Income per Diluted Share				
Net (loss) income, as reported, per diluted share	\$ (0.06)	\$ (0.06)	\$ 0.05	\$ 0.03
Interest expense on convertible notes	0.02	N/A	0.04	N/A
Dilutive effect of convertible notes	0.01	N/A	(0.01)	N/A
Non-cash, stock-based compensation	0.06	0.08	0.12	0.18
Restructuring charges	0.05	0.14	0.07	0.14
Inventory step-up amortization	-	0.00	0.00	0.00
Department of Justice inquiry	0.02	-	0.04	-
Appellate court decision	0.04	-	0.04	-
Acquired in-process research and development	0.06	-	0.06	-
Net income, as adjusted, per diluted share	<u>\$ 0.19</u>	<u>\$ 0.17</u>	<u>\$ 0.41</u>	<u>\$ 0.35</u>

Wright Medical Group, Inc.
Reconciliation of Effective Tax Rate, As Reported, to Effective Tax Rate, As Adjusted
(unaudited)

	<u>Three Months Ended</u>		<u>Six Months Ended</u>	
	<u>June 30,</u> <u>2008</u>	<u>June 30,</u> <u>2007</u>	<u>June 30,</u> <u>2008</u>	<u>June 30,</u> <u>2007</u>
Effective tax rate, as reported	(45.1%)	(0.3%)	70.4%	62.8%
Non-cash, stock-based expense	(3.9%)	(9.9%)	(4.0%)	(7.7%)
Restructuring charges	167.5%	46.7%	(16.2%)	(21.0%)
Inventory step-up amortization	-	(0.3%)	0.0%	(0.1%)
Department of Justice inquiry	(0.7%)	-	(0.6%)	-
Appellate court decision	(2.4%)	-	(0.8%)	-
Acquired in-process research and development	(76.9%)	-	(10.3%)	-
Effective tax rate, as adjusted	<u>38.5%</u>	<u>36.2%</u>	<u>38.5%</u>	<u>34.0%</u>